Nocebo in fibromyalgia: Meta-analysis of placebo-controlled clinical trials and implications for practice

European Journal of Neurology

Volumn 19, Issue 5, 2012, Pages 672-680

  Mitsikostas, D D ^a   Chalarakis, N G ^a   Mantonakis, L I ^a   Delicha, E M ^a,b   Sfikakis, P P ^b  

^a ATHENS NAVAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Fibromyalgia; Meta analysis; Nocebo; Placebo

Indexed keywords

PLACEBO;

ANXIETY; ASTHENIA; CLINICAL PRACTICE; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FIBROMYALGIA; FLU LIKE SYNDROME; HEADACHE; HEALTH CARE COST; HEART PALPITATION; HOT FLUSH; HUMAN; INFECTION; INSOMNIA; LEG CRAMP; MEDLINE; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

FIBROMYALGIA; HUMANS; MEDLINE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859879434     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03528.x     Document Type: Review

References (38)

1. Clauw DJ Fibromyalgia: an overview. Am J Med 2009;122(12 Suppl):S3-S13.
2. Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009; 11: 117-118.
3. Lawrence RC, Felson DT, Helmick CG, et al. National Arthritis Work Group: estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58: 26-35.
4. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010; 39: 448-453.
5. Sicras-Mainar A, Rejas J, Navarro R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009; 2: R54.
6. Gatter RA. Pharmacotherapeutics in fibrositis. Am J Med 1986; 3A: 63-66.
7. Dobkin PL, Sita A, Sewitch MJ. Predictors of adherence to treatment in women with fibromyalgia. Clin J Pain 2006; 3: 286-294.
8. Zhao Y, Chen SY, Wu N, Fraser KA, Boulanger L. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine. Pain Pract 2011; 11: 381-391.
9. Amanzion M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009; 146: 261-269.
10. Kennedy WP. The nocebo reaction. Med World 1961; 95: 203-205.
11. Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron 2008; 59: 195-206.
12. Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain 2008; 136: 211-218.
13. Benedetti F, Amanzio M, Vighetti S, Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 2006; 26: 12014-12022.
14. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003; 23: 4315-4323.
15. Benedetti F, Amanzio M, Casadio C, Oliaro A, Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 1997; 71: 135-140.
16. Kong J, Gollub RL, Polich G, et al. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci 2008; 28: 13354-13362.
17. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008; 65: 220-231.
18. Johansen O, Brox J, Flaten MA. Placebo and nocebo responses, cortisol, and circulating beta-endorphin. Psychosom Med 2003; 65: 786-790.
19. Lorenz J, Hauck M, Paur RC, et al. Cortical correlates of false expectations during pain intensity judgments-a possible manifestation of placebo/nocebo cognitions. Brain Behav Immun 2005; 19: 283-295.
20. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 2003; 105: 17-25.
21. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287: 622-627.
22. Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis for nocebo in headaches. Cephalalgia 2011; 5: 550-556.
23. Reuter U, Sanchez del Rio M, Carpay JA, Boes CJ, Silberstein SD. GSK Headache Masters Program. Placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia 2003; 23: 496-503.
24. Papadopoulos D, Mitsikostas DD. Nocebo effect in multiple sclerosis. Mult Scler 2010; 16: 816-828.
25. Preston RA, Materson BJ, Reda DJ, Williams DW. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study. Arch Intern Med 2000; 160: 1449-1454.
26. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-269.
27. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-172.
28. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
29. Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 2008; 88: 156-175.
30. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
31. Cohran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 110-129.
32. Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract 2008; 14: 951-957.
33. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
34. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Systematic reviews of trials and other studies. Health Technol Assess 1998; 2: 1-276.
35. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003; 65: 528-533.
36. Aguglia A, Salvi V, Maina G, Rossetto I, Aguglia E. Fibromyalgia syndrome and depressive symptoms: comorbidity and clinical correlates. J Affect Disord 2011; 3: 262-266.
37. Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 2007; 147: 260-271.
38. Craig P, Dieppe P, Macintype S, Michie S, Nazzareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008; 337: 979-983.